What is China Pharma Holdings, Inc.'s earnings per share (EPS)?

China Pharma Holdings, Inc. (CPHI) reported diluted earnings per share of -$0.74 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

China Pharma Holdings, Inc. (CPHI) Financials

CPHI

FY2025 annual

Revenue $4.1M -8.5% YoY

Net Income -$3.2M +32.7% YoY

EPS (Diluted) -$0.74 YoY not available

Free Cash Flow $89K +120.0% YoY

Market Cap $32.3M as of Oct 13, 2026

Price / Sales 8.3x on $3.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.9x on $36.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CPHI SEC filings page.

China Pharma Holdings, Inc. (CPHI) reported $4.1M in revenue for fiscal year 2025, down 8.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CPHI FY2025 2026-10-04

The business still loses money at the product level, while shrinking sales and weak near-term liquidity overshadow a one-year cash-flow improvement.

FY2025 is the first period in this set where both operating cash flow and free cash flow were positive, even though the company still posted a net loss. Positive cash generation arrived alongside a net loss of $3.2M, unlike FY2024's negative free cash flow; cash conversion improved before profitability did.

Sales fell from $9.6M in FY2021 to $4.1M, leaving a smaller revenue base to absorb operating costs. Gross margin moved from 3.6% to -3.2%, indicating that product costs still exceeded sales in FY2025 rather than merely reflecting slower growth.

Assets rose to $31.0M while debt-to-equity fell to 0.4x, indicating a less debt-heavy capital structure. Yet the current ratio was 0.3x against current liabilities of $7.4M, so improved overall capitalization has not removed near-term balance-sheet tightness.

Financial Health Signals

Financial Health Score 40/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of China Pharma Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

China Pharma Holdings, Inc. held $345K in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $148K of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and China Pharma Holdings, Inc. scores 86/100 among other emerging companies.

Dilution

China Pharma Holdings, Inc. had 41M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and China Pharma Holdings, Inc. scores 16/100 among other emerging companies.

R&D Intensity

China Pharma Holdings, Inc. spent $281K on research and development in fiscal year 2025, which was 3.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and China Pharma Holdings, Inc. scores 20/100 among other emerging companies.

Revenue Progress

China Pharma Holdings, Inc. reported revenue of $4.1M in fiscal year 2025, against $4.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and China Pharma Holdings, Inc. scores 17/100 among other emerging companies.

Burn Trend

China Pharma Holdings, Inc.'s operations generated $148K of cash in fiscal year 2025, against $406K used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and China Pharma Holdings, Inc. scores 90/100 among other emerging companies.

Balance Sheet

China Pharma Holdings, Inc.'s cash, cash equivalents and investments came to $345K at the end of fiscal year 2025, against $8.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and China Pharma Holdings, Inc. scores 8/100 among other emerging companies.

Altman Z-Score Distress

-0.19

China Pharma Holdings, Inc. scores -0.19, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($32.3M) relative to total liabilities ($8.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

China Pharma Holdings, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

China Pharma Holdings, Inc. reported a net loss of $3.2M while generating $148K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

China Pharma Holdings, Inc. reported an operating loss of $3.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$948K

YoY-7.5%

QoQ-3.6%

5Y CAGR-17.1%

10Y CAGR-12.3%

China Pharma Holdings, Inc. generated $948K in revenue in Q2 2026. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is down 3.6%.

EBITDA

-$330K

YoY+0.4%

QoQ-141.4%

China Pharma Holdings, Inc.'s EBITDA was -$330K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.4% from the same quarter a year earlier. Against the prior quarter it is down 141.4%.

Net Income

-$1.5M

YoY-176.0%

QoQ-27.6%

China Pharma Holdings, Inc. reported -$1.5M in net income in Q2 2026. This represents a decrease of 176.0% from the same quarter a year earlier. Against the prior quarter it is down 27.6%.

EPS (Diluted)

-$0.04

QoQ0.0%

China Pharma Holdings, Inc. earned -$0.04 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.

Cash & Balance Sheet

Cash & Debt

$305K

YoY-49.2%

QoQ+81.0%

5Y CAGR-29.5%

10Y CAGR-26.1%

China Pharma Holdings, Inc. held $305K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

43M

QoQ+6.2%

China Pharma Holdings, Inc. had 43M shares outstanding in Q2 2026. Against the prior quarter it is up 6.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

8.8%

YoY+17.3pp

QoQ-20.2pp

5Y change+5.9pp

10Y change-4.8pp

China Pharma Holdings, Inc.'s gross margin was 8.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 17.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.2 percentage points.

Return on Equity

-4.0%

YoY+4.1pp

QoQ-0.9pp

5Y change+8.6pp

10Y change-0.4pp

China Pharma Holdings, Inc.'s ROE was -4.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$19K

YoY-8.7%

QoQ-77.2%

5Y CAGR-18.6%

10Y CAGR-15.0%

China Pharma Holdings, Inc. invested $19K in research and development in Q2 2026. This represents a decrease of 8.7% from the same quarter a year earlier. Against the prior quarter it is down 77.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

CPHI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CPHI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.9M	$4.1M-8.5%	$4.5M-35.4%	$7.0M-13.5%	$8.1M-15.9%	$9.6M-11.3%	$10.9M-0.5%	$10.9M-11.4%	$12.3M-6.7%	$13.2M-15.1%	$15.6M-23.5%	$20.4M-8.1%	$22.1M-32.5%	$32.8M-39.8%	$54.5M-32.8%	$81.2M
Cost of Revenue	$3.5M	$4.3M-34.4%	$6.5M-10.7%	$7.3M-15.2%	$8.6M-7.5%	$9.3M+4.3%	$8.9M-5.6%	$9.4M-8.8%	$10.4M-3.6%	$10.7M-13.0%	$12.4M-21.7%	$15.8M-8.3%	$17.2M-26.4%	$23.4M-39.5%	$38.7M-25.9%	$52.2M
Gross Profit	$460K	-$132K+93.4%	-$2.0M-606.4%	-$281K+43.1%	-$494K-241.4%	$349K-82.1%	$2.0M+31.8%	$1.5M-24.9%	$2.0M-20.0%	$2.5M-23.3%	$3.2M+119.8%	$1.5M-45.1%	$2.7M-71.6%	$9.4M-33.2%	$14.1M-51.4%	$29.0M
R&D Expenses	$333K	$281K-1.1%	$284K+18.3%	$240K+29.2%	$186K-41.7%	$319K-15.6%	$378K+64.6%	$230K+33.2%	$172K+90.5%	$90K-75.3%	$366K-62.0%	$962K-65.6%	$2.8M+66.3%	$1.7M+283.7%	$439K	N/A
SG&A Expenses	$4.1M	$2.5M+37.4%	$1.8M+21.7%	$1.5M-22.6%	$1.9M+14.7%	$1.7M-9.4%	$1.8M-20.4%	$2.3M+17.4%	$1.9M-3.5%	$2.0M-10.9%	$2.3M+19.5%	$1.9M+10.5%	$1.7M-28.6%	$2.4M-16.4%	$2.9M-22.6%	$3.7M
Operating Income	-$4.4M	-$3.2M+29.4%	-$4.6M-66.8%	-$2.8M+22.5%	-$3.5M-24.1%	-$2.9M-10.9%	-$2.6M+87.4%	-$20.4M-95.3%	-$10.4M+44.1%	-$18.7M-129.0%	-$8.2M+43.0%	-$14.3M+63.1%	-$38.8M-108.3%	-$18.6M-415.1%	$5.9M-73.2%	$22.0M
EBITDA	N/A	-$1.7M+11.9%	-$2.0M-107617.7%	$2K+100.2%	-$848K-473.3%	$227K+124.7%	$101K+100.6%	-$17.5M-143.1%	-$7.2M+53.3%	-$15.4M-203.1%	-$5.1M+52.6%	-$10.7M+71.1%	-$37.0M-117.6%	-$17.0M-330.6%	$7.4M-68.2%	$23.2M
Interest Expense	$32K	$27K-0.3%	$27K-10.5%	$31K-93.0%	$435K-19.8%	$542K+84.3%	$294K-8.6%	$322K-28.7%	$451K-16.3%	$539K-36.5%	$850K+172.9%	-$1.2M-248.3%	$786K+325.4%	-$349K-13.1%	-$308K-20.8%	-$255K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$110K-189.7%	$123K-60.2%	$308K+409.9%	$60K+178.4%	-$77K+92.7%	-$1.1M-7.9%	-$984K+71.4%	-$3.4M
Net Income	-$4.5M	-$3.2M+32.7%	-$4.7M-53.8%	-$3.1M+22.5%	-$4.0M-16.9%	-$3.4M-18.6%	-$2.9M+86.2%	-$20.7M-92.6%	-$10.8M+44.2%	-$19.3M-109.9%	-$9.2M+40.4%	-$15.4M+61.0%	-$39.6M-97.7%	-$20.0M-533.3%	$4.6M-76.0%	$19.3M
EPS (Basic)	N/A	-$0.74+72.7%	-$2.71-197.8%	-$0.91+75.9%	-$3.78-410.8%	-$0.74	N/A	N/A	N/A	N/A	N/A	-$0.35+61.5%	-$0.91-97.8%	-$0.46-518.2%	$0.11-75.0%	$0.44
EPS (Diluted)	—	-$0.74	-$2.71	-$0.91	-$3.78	-$0.74	N/A	N/A	N/A	N/A	N/A	-$0.35+61.5%	-$0.91-97.8%	-$0.46-518.2%	$0.11-75.0%	$0.44
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	44M0.0%	44M	N/A	44M+0.2%	43M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$948K-7.5%	$984K-13.4%	$1.2M+8.1%	$756K-31.3%	$1.0M+10.9%	$1.1M-17.0%	$1.1M-47.2%	$1.1M-39.0%
Cost of Revenue	$865K-22.3%	$698K-45.1%	$1.1M-16.9%	$816K-49.6%	$1.1M-42.7%	$1.3M-23.3%	$1.3M-41.9%	$1.6M-20.5%
Gross Profit	$84K+196.0%	$285K+309.8%	$151K+193.9%	-$60K+88.5%	-$87K+91.4%	-$136K+53.1%	-$161K-102.9%	-$520K-122.8%
R&D Expenses	$19K-8.7%	$84K+183.1%	$190K+34642.4%	$40K-54.0%	$21K-87.3%	$30K-5.9%	$547-99.6%	$88K+91.4%
SG&A Expenses	$1.4M+212.4%	$1.2M+141.8%	$1.1M+25.5%	$425K+23.1%	$441K+379.8%	$507K+3.8%	$859K+24.6%	$345K+40.1%
Operating Income	-$1.4M-119.6%	-$1.1M-47.3%	-$1.2M-0.3%	-$628K+42.1%	-$652K+53.1%	-$759K+17.2%	-$1.2M-1.0%	-$1.1M-52.1%
EBITDA	-$330K+0.4%	-$137K+68.2%	-$703K-7.9%	-$272K+44.2%	-$331K+49.0%	-$429K-135.6%	-$651K-33.0%	-$487K-1500.2%
Interest Expense	$9K+37.4%	$9K+33.9%	$7K+1.7%	$7K-0.7%	$7K-1.2%	$7K-1.0%	$7K+103.5%	$7K-1.4%
Net Income	-$1.5M-176.0%	-$1.1M-45.5%	-$1.2M+0.2%	-$651K+41.7%	-$528K+63.3%	-$786K+17.8%	-$1.2M+0.6%	-$1.1M-43.8%
EPS (Basic)	-$0.04+75.0%	-$0.04+83.3%	-$0.17-325.0%	-$0.17+73.8%	-$0.16+82.0%	-$0.24+66.7%	-$0.04-100.0%	-$0.65-124.1%
EPS (Diluted)	-$0.04	-$0.04	-$0.17	-$0.17	-$0.16	-$0.24	-$0.04	-$0.65
Diluted Shares (Avg)	41M	26M	N/A	N/A	3M	3M	N/A	N/A

Not reported in any period shown, so not listed: Income Tax.

CPHI Balance Sheet

CPHI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$31.0M+108.2%	$14.9M-9.6%	$16.5M-7.4%	$17.8M-21.5%	$22.6M+7.3%	$21.1M-5.0%	$22.2M-51.0%	$45.4M-24.3%	$60.0M-23.6%	$78.5M-18.6%	$96.5M-20.3%	$121.1M-23.2%	$157.6M-3.4%	$163.2M+4.4%	$156.4M
Current Assets	$2.3M-28.3%	$3.3M-45.5%	$6.0M+0.5%	$6.0M-34.4%	$9.1M+70.9%	$5.3M-4.6%	$5.6M-36.2%	$8.7M-28.8%	$12.3M-29.9%	$17.5M-27.7%	$24.2M-42.1%	$41.9M-50.1%	$84.0M-25.4%	$112.5M+1.7%	$110.6M
Cash & Equivalents	$345K-44.9%	$627K-56.0%	$1.4M-29.9%	$2.0M-58.2%	$4.9M+407.4%	$958K-10.9%	$1.1M-9.4%	$1.2M-41.6%	$2.0M-23.8%	$2.7M-57.3%	$6.2M+18.0%	$5.3M-11.6%	$6.0M+48.7%	$4.0M-0.5%	$4.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.6M-28.5%	$2.3M-39.3%	$3.7M+26.6%	$2.9M0.0%	$2.9M-20.4%	$3.7M+3.2%	$3.6M-29.0%	$5.1M-21.1%	$6.4M-12.4%	$7.3M-24.3%	$9.7M-36.9%	$15.3M-37.9%	$24.7M-32.1%	$36.4M+19.7%	$30.4M
Accounts Receivable	$241K+4.0%	$232K-54.0%	$504K+19.7%	$422K	N/A	N/A	N/A	N/A	$2.3M-42.7%	$4.0M-32.0%	$5.9M-57.5%	$13.9M-69.3%	$45.1M-31.8%	$66.2M-5.1%	$69.7M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.3M+15.7%	$7.1M-20.8%	$9.0M-33.2%	$13.5M-18.9%	$16.6M+26.8%	$13.1M+0.9%	$13.0M-14.4%	$15.2M-10.1%	$16.9M-13.9%	$19.6M-17.9%	$23.9M-15.8%	$28.3M+14.9%	$24.7M+67.5%	$14.7M+5.9%	$13.9M
Current Liabilities	$7.4M+47.5%	$5.0M-26.4%	$6.8M-46.5%	$12.7M+21.2%	$10.5M-7.8%	$11.4M+13.5%	$10.0M-0.1%	$10.1M+8.9%	$9.2M-11.3%	$10.4M-18.7%	$12.8M-9.7%	$14.2M+18.0%	$12.0M-17.9%	$14.6M+6.2%	$13.8M
Non-Current Liabilities	$859K-59.5%	$2.1M-3.3%	$2.2M+190.7%	$755K-87.7%	$6.1M+257.9%	$1.7M-42.1%	$3.0M-42.4%	$5.1M-33.0%	$7.7M-16.9%	$9.2M-16.9%	$11.1M-21.8%	$14.2M+11.9%	$12.7M+13093.2%	$96K-25.6%	$129K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$5.2M+21.9%	$4.3M-34.3%	$6.5M-29.0%	$9.2M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$22.7M+193.5%	$7.7M+3.9%	$7.5M+73.8%	$4.3M-28.7%	$6.0M-24.8%	$8.0M-13.3%	$9.2M-69.4%	$30.2M-29.9%	$43.1M-26.9%	$58.9M-18.9%	$72.6M-21.7%	$92.7M-30.2%	$132.9M-10.5%	$148.5M+4.2%	$142.5M
Retained Earnings	-$47.2M-7.2%	-$44.0M-12.1%	-$39.3M-8.5%	-$36.2M-12.3%	-$32.2M-11.8%	-$28.8M-11.0%	-$26.0M-392.8%	-$5.3M-196.2%	$5.5M-77.9%	$24.8M-27.1%	$33.9M-31.2%	$49.3M-44.5%	$88.9M-18.4%	$108.9M+4.4%	$104.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$44.7M+224.8%	$45.1M+217.5%	$31.0M+108.2%	$15.8M+17.4%	$13.8M-3.5%	$14.2M	$14.9M-9.6%	$13.5M-12.3%
Current Assets	$2.0M-25.7%	$2.0M-29.7%	$2.3M-28.3%	$2.3M-37.7%	$2.7M-32.0%	$2.9M	$3.3M-45.5%	$3.7M-35.6%
Cash & Equivalents	$305K-49.2%	$168K-57.9%	$345K-44.9%	$268K-61.8%	$600K-18.8%	$400K-52.3%	$627K-56.0%	$700K-48.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.4M-18.8%	$1.5M-24.3%	$1.6M-28.5%	$1.6M-34.0%	$1.7M-40.4%	$2.0M	$2.3M-39.3%	$2.5M-33.7%
Accounts Receivable	$182K-32.4%	$196K-40.3%	$241K+4.0%	$225K-32.6%	$269K+5.5%	$329K	$232K-54.0%	$333K-9.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.5M+16.8%	$8.1M+12.0%	$8.3M+15.7%	$7.5M+8.0%	$7.3M+6.6%	$7.2M	$7.1M-20.8%	$6.9M-24.9%
Current Liabilities	$7.7M+46.3%	$7.3M+41.9%	$7.4M+47.5%	$6.6M+39.1%	$5.3M+11.4%	$5.1M	$5.0M-26.4%	$4.8M-32.6%
Non-Current Liabilities	$847K-58.8%	$852K-59.9%	$859K-59.5%	$868K-60.1%	$2.1M-4.0%	$2.1M	$2.1M-3.3%	$2.2M-0.3%
Total Equity	$36.2M+459.9%	$37.0M+431.2%	$22.7M+193.5%	$8.3M+27.4%	$6.5M-12.8%	$7.0M-15.9%	$7.7M+3.9%	$6.5M+6.8%
Retained Earnings	-$49.8M-9.9%	-$48.4M-7.9%	-$47.2M-7.2%	-$46.0M-7.5%	-$45.3M-8.8%	-$44.8M	-$44.0M-12.1%	-$42.8M-12.5%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

CPHI Cash Flow Statement

CPHI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$140K	$148K+136.5%	-$406K+42.0%	-$700K-70.8%	-$410K-63.9%	-$250K-491.2%	-$42K-106.9%	$608K-67.7%	$1.9M+123.7%	$841K-70.9%	$2.9M-13.6%	$3.4M-45.6%	$6.2M-28.4%	$8.6M+135.9%	$3.6M-30.4%	$5.2M
Depreciation & Amortization	N/A	$1.5M-42.6%	$2.6M-4.9%	$2.8M+2.0%	$2.7M-12.5%	$3.1M+15.2%	$2.7M-8.5%	$2.9M-10.1%	$3.3M-1.0%	$3.3M+6.9%	$3.1M-14.5%	$3.6M+101.5%	$1.8M+10.7%	$1.6M+10.3%	$1.5M+24.5%	$1.2M
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$142K-27.8%	$196K
Capital Expenditures	N/A	$59K+54.4%	$38K+233.5%	$12K-97.1%	$402K-8.2%	$438K-49.5%	$867K+537.7%	$136K+165.9%	$51K-62.5%	$136K-29.4%	$193K-71.8%	-$685K-86.6%	$5.1M-72.7%	-$18.8M+11880.2%	-$157K-55.5%	-$352K
Free Cash Flow	N/A	$89K+120.0%	-$444K+37.5%	-$711K+12.4%	-$812K-18.0%	-$688K+24.4%	-$910K-292.6%	$472K-74.2%	$1.8M+159.8%	$705K-73.9%	$2.7M+1.4%	$2.7M+160.2%	$1.0M+110.0%	-$10.2M-392.5%	$3.5M-28.6%	$4.9M
Investing Cash Flow	N/A	-$137K+53.0%	-$292K-2432.9%	-$12K+97.1%	-$402K+8.2%	-$438K+49.5%	-$867K-537.7%	-$136K-165.9%	-$51K+62.5%	-$136K+29.4%	-$193K+89.8%	-$1.9M+74.5%	-$7.4M+61.1%	-$19.1M-282.8%	-$5.0M+11.3%	-$5.6M
Financing Cash Flow	-$154K	-$294K-770.4%	-$34K-146.2%	$73K+104.1%	-$1.8M-138.5%	$4.6M+636.6%	$624K+136.1%	-$1.7M+12.5%	-$2.0M-33.5%	-$1.5M+75.4%	-$6.0M	$0-100.0%	$605K-95.1%	$12.3M+858.0%	$1.3M+115.9%	$596K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$33K-112.0%	-$55K+25.0%	$152K-49.1%	-$204K-335.3%	$274K+477.2%	-$74K+87.4%	$299K+1438.4%	-$47K-104.7%
Depreciation & Amortization	$1.1M+243.4%	$981K+197.8%	$497K+11.0%	$356K-40.5%	$321K-56.7%	$329K-55.1%	$448K-35.6%	$598K-12.5%
Stock-Based Compensation	$0	$0	N/A	N/A	$0	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	$454-97.7%	$611-93.4%	-$65	$58K	$20K	-$9K
Free Cash Flow	N/A	N/A	$152K-45.7%	-$205K-264.9%	$274K	-$132K	$279K	-$56K
Investing Cash Flow	N/A	N/A	-$6K+97.9%	-$73K-894.2%	$65	-$58K	-$273K-5927.2%	$9K+113.7%
Financing Cash Flow	$120K+636.2%	-$79K-3.3%	-$73K-33.6%	-$122K-1886.0%	-$22K-426.9%	-$77K-1220.5%	-$54K-278.9%	$7K+101.4%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CPHI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CPHI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	-3.2%+40.7pp	-43.8%-39.8pp	-4.0%+2.1pp	-6.1%-9.7pp	3.6%-14.3pp	18.0%+4.4pp	13.6%-2.5pp	16.0%-2.7pp	18.7%-2.0pp	20.7%+13.5pp	7.2%-4.9pp	12.0%-16.6pp	28.7%+2.8pp	25.8%-9.9pp	35.7%
Operating Margin	-78.2%	-101.3%	-39.3%+4.5pp	-43.8%-14.1pp	-29.7%-5.9pp	-23.7%	-186.8%	-84.7%	-141.4%	-52.4%+17.9pp	-70.3%	-175.1%	-56.7%-67.5pp	10.8%-16.3pp	27.1%
Net Margin	-76.9%	-104.6%	-43.9%+5.1pp	-49.0%-13.8pp	-35.3%-8.9pp	-26.4%	-189.5%	-87.2%	-145.9%	-59.0%+16.7pp	-75.7%	-178.7%	-61.0%-69.5pp	8.5%-15.3pp	23.7%
Return on Equity	-14.0%+47.1pp	-61.1%-19.8pp	-41.3%+51.3pp	-92.6%-36.1pp	-56.5%-20.7pp	-35.8%+188.3pp	-224.1%-188.5pp	-35.6%+9.2pp	-44.8%-29.2pp	-15.6%+5.6pp	-21.2%+21.4pp	-42.6%-27.6pp	-15.0%-18.2pp	3.1%-10.4pp	13.5%
Return on Assets	-10.3%+21.5pp	-31.8%-13.1pp	-18.7%+3.6pp	-22.3%-7.3pp	-15.0%-1.4pp	-13.6%+79.5pp	-93.1%-69.4pp	-23.7%+8.5pp	-32.1%-20.5pp	-11.7%+4.3pp	-16.0%+16.7pp	-32.7%-20.0pp	-12.7%-15.5pp	2.8%-9.5pp	12.3%
Current Ratio	0.32-0.3x	0.65-0.2x	0.88+0.4x	0.47-0.4x	0.86+0.4x	0.47-0.1x	0.56-0.3x	0.87-0.5x	1.33-0.4x	1.69-0.2x	1.90-1.1x	2.96-4.0x	6.99-0.7x	7.69-0.3x	8.03
Debt-to-Equity	0.36-0.6x	0.92-0.3x	1.21-1.9x	3.15+0.4x	2.76+2.1x	0.65+0.2x	0.47+0.2x	0.220.0x	0.21-0.1x	0.330.0x	0.330.0x	0.31+0.1x	0.19+0.1x	0.100.0x	0.10
Asset Turnover	0.13-0.2x	0.30-0.1x	0.430.0x	0.460.0x	0.43-0.1x	0.510.0x	0.49+0.2x	0.27+0.1x	0.220.0x	0.200.0x	0.210.0x	0.180.0x	0.21-0.1x	0.33-0.2x	0.52
FCF Margin	2.1%+12.0pp	-9.8%+0.3pp	-10.1%-0.1pp	-10.0%-2.9pp	-7.1%+1.2pp	-8.4%-12.7pp	4.3%-10.5pp	14.8%+9.5pp	5.3%-12.0pp	17.4%+4.3pp	13.1%+8.5pp	4.6%+35.7pp	-31.1%-37.5pp	6.4%+0.4pp	6.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	8.8%+17.3pp	29.0%+41.0pp	12.3%+26.5pp	-7.9%+39.3pp	-8.5%	-12.0%+9.2pp	-14.2%-10.5pp	-47.2%-34.3pp
Operating Margin	-151.0%	-113.6%	-97.9%	-83.1%+15.6pp	-63.6%	-66.8%+0.1pp	-105.5%	-98.7%-59.1pp
Net Margin	-153.8%	-116.2%	-99.7%	-86.2%	-51.5%	-69.1%+0.6pp	-108.0%	-101.6%
Return on Equity	-4.0%+4.1pp	-3.1%+8.2pp	-5.4%+10.4pp	-7.8%+9.3pp	-8.2%+11.2pp	-11.3%+0.3pp	-15.8%+0.7pp	-17.1%-4.4pp
Return on Assets	-3.3%+0.6pp	-2.5%+3.0pp	-3.9%+4.3pp	-4.1%+4.2pp	-3.8%+6.2pp	-5.5%	-8.2%-0.7pp	-8.3%-3.2pp
Current Ratio	0.26-0.3x	0.28-0.3x	0.32-0.3x	0.35-0.4x	0.51-0.3x	0.56	0.65-0.2x	0.790.0x
Debt-to-Equity	0.24-0.9x	0.22-0.8x	0.36-0.6x	0.90-0.2x	1.13+0.2x	1.04	0.92-0.3x	1.06-0.4x
Asset Turnover	0.02-0.1x	0.02-0.1x	0.040.0x	0.050.0x	0.070.0x	0.08	0.08-0.1x	0.080.0x
FCF Margin	N/A	N/A	12.4%-12.3pp	-27.1%-22.0pp	26.7%	-11.6%	24.6%	-5.1%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: The current ratio is below 1.0 (0.32), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
China Pharma Holdings, Inc. CPHI	FY2025	$4.1M	-$3.2M	-76.9%	$32.3M	40/100
cbdMD, Inc. YCBD	FY2025	$19.2M	-$2.0M	-10.6%	$4.0M	38/100
Sunshine Biopharma Inc. SBFM	FY2025	$36.3M	-$6.0M	-16.5%	$1.2M	59/100
Evoke Pharma, Inc. EVOK	FY2024	$10.2M	-$5.4M	-52.2%	$18.9M	58/100
Sonoma Pharmaceuticals, Inc. SNOA	FY2026	$19.5M	$3K	0.0%	$5.9M	40/100
Biofrontera Inc. BFRI	FY2025	$41.7M	-$10.5M	-25.3%	$13.7M	39/100

Where China Pharma Holdings, Inc. Ranks

Frequently Asked Questions

What is China Pharma Holdings, Inc.'s annual revenue?

China Pharma Holdings, Inc. (CPHI) reported $4.1M in total revenue for fiscal year 2025. This represents a -8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is China Pharma Holdings, Inc.'s revenue growing?

China Pharma Holdings, Inc. (CPHI) revenue declined by 8.5% year-over-year, from $4.5M to $4.1M in fiscal year 2025.

Is China Pharma Holdings, Inc. profitable?

No, China Pharma Holdings, Inc. (CPHI) reported a net income of -$3.2M in fiscal year 2025, with a net profit margin of -76.9%.

What is China Pharma Holdings, Inc.'s EBITDA?

China Pharma Holdings, Inc. (CPHI) had EBITDA of -$1.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is China Pharma Holdings, Inc.'s gross margin?

China Pharma Holdings, Inc. (CPHI) had a gross margin of -3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is China Pharma Holdings, Inc.'s operating margin?

China Pharma Holdings, Inc. (CPHI) had an operating margin of -78.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is China Pharma Holdings, Inc.'s net profit margin?

China Pharma Holdings, Inc. (CPHI) had a net profit margin of -76.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is China Pharma Holdings, Inc.'s return on equity (ROE)?

China Pharma Holdings, Inc. (CPHI) has a return on equity of -14.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is China Pharma Holdings, Inc.'s free cash flow?

China Pharma Holdings, Inc. (CPHI) generated $89K in free cash flow during fiscal year 2025. This represents a 120.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is China Pharma Holdings, Inc.'s operating cash flow?

China Pharma Holdings, Inc. (CPHI) generated $148K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are China Pharma Holdings, Inc.'s total assets?

China Pharma Holdings, Inc. (CPHI) had $31.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are China Pharma Holdings, Inc.'s capital expenditures?

China Pharma Holdings, Inc. (CPHI) invested $59K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does China Pharma Holdings, Inc. spend on research and development?

China Pharma Holdings, Inc. (CPHI) invested $281K in research and development during fiscal year 2025.

How many shares does China Pharma Holdings, Inc. have outstanding?

China Pharma Holdings, Inc. (CPHI) had 41M shares outstanding as of fiscal year 2025.

What is China Pharma Holdings, Inc.'s current ratio?

China Pharma Holdings, Inc. (CPHI) had a current ratio of 0.32 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is China Pharma Holdings, Inc.'s debt-to-equity ratio?

China Pharma Holdings, Inc. (CPHI) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is China Pharma Holdings, Inc.'s return on assets (ROA)?

China Pharma Holdings, Inc. (CPHI) had a return on assets of -10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is China Pharma Holdings, Inc.'s P/E ratio?

China Pharma Holdings, Inc. (CPHI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $32.3M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is China Pharma Holdings, Inc.'s price-to-sales ratio?

China Pharma Holdings, Inc. (CPHI) trades at 8.3x sales, its market capitalization divided by revenue of $3.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $32.3M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is China Pharma Holdings, Inc.'s Altman Z-Score?

China Pharma Holdings, Inc. (CPHI) has an Altman Z-Score of -0.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is China Pharma Holdings, Inc.'s Piotroski F-Score?

China Pharma Holdings, Inc. (CPHI) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are China Pharma Holdings, Inc.'s earnings high quality?

China Pharma Holdings, Inc. (CPHI) reported a net loss of $3.2M while generating $148K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can China Pharma Holdings, Inc. cover its interest payments?

China Pharma Holdings, Inc. (CPHI) reported an operating loss of $3.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is China Pharma Holdings, Inc.?

China Pharma Holdings, Inc. (CPHI) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.